At the time of writing, Lexicon Pharmaceuticals Inc [LXRX] stock is trading at $2.03, up 9.14%. An important factor to consider is whether the stock is rising or falling in short-term value. The LXRX shares have gain 4.64% over the last week, with a monthly amount glided 29.30%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] stock has seen the most recent analyst activity on June 17, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $10. Previously, Leerink Partners started tracking the stock with Outperform rating on April 30, 2024, and set its price target to $5. On March 07, 2023, Jefferies initiated with a Hold rating and assigned a price target of $3 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $10 on August 12, 2022. JP Morgan upgraded its rating to a Neutral but $7 remained the price target by the analyst firm on January 29, 2021. Wedbush downgraded its rating to Neutral for this stock on January 29, 2021, and upped its price target to $8. In a note dated December 08, 2020, Citigroup upgraded an Buy rating on this stock.
For the past year, the stock price of Lexicon Pharmaceuticals Inc fluctuated between $0.92 and $3.73. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] shares were valued at $2.03 at the most recent close of the market. An investor can expect a potential return of 195.57% based on the average LXRX price forecast.
Analyzing the LXRX fundamentals
According to Lexicon Pharmaceuticals Inc [NASDAQ:LXRX], the company’s sales were 3.64M for trailing twelve months, which represents an 419.56% jump. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -54.12%, Pretax Profit Margin comes in at -55.09%, and Net Profit Margin reading is -55.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is 0.73 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.42.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8900 points at the first support level, and at 1.7500 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1200, and for the 2nd resistance point, it is at 2.2200.
Ratios To Look Out For
It is important to note that Lexicon Pharmaceuticals Inc [NASDAQ:LXRX] has a current ratio of 11.51. On the other hand, the Quick Ratio is 11.49, and the Cash Ratio is 1.28. Considering the valuation of this stock, the price to sales ratio is 201.60, the price to book ratio is 3.06.
Transactions by insiders
Recent insider trading involved COATS LONNEL, Former Affiliate, that happened on Aug 15 ’24 when 0.3 million shares were purchased. Chief Executive Officer, COATS LONNEL completed a deal on Nov 16 ’23 to buy 90000.0 shares. Meanwhile, Chief Executive Officer COATS LONNEL bought 10000.0 shares on Nov 10 ’23.
